[go: up one dir, main page]

MX2007015933A - Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales. - Google Patents

Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales.

Info

Publication number
MX2007015933A
MX2007015933A MX2007015933A MX2007015933A MX2007015933A MX 2007015933 A MX2007015933 A MX 2007015933A MX 2007015933 A MX2007015933 A MX 2007015933A MX 2007015933 A MX2007015933 A MX 2007015933A MX 2007015933 A MX2007015933 A MX 2007015933A
Authority
MX
Mexico
Prior art keywords
compositions
methods
expressed
cancer cells
immune responses
Prior art date
Application number
MX2007015933A
Other languages
English (en)
Inventor
Adrian Bot
Zhiyong Qiu
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of MX2007015933A publication Critical patent/MX2007015933A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion proporciona un metodo para tratar cancer suministrado al sujeto que lo necesita una composicion inmunogenica que comprende una construccion de acido nucleico que codifica a un polipeptido que comprende epitopes CTL PSMA288-297 y PRAME425-4433, o un analogo reactivo transversal. En las modalidades de la presente invencion se proporcionan metodos y composiciones para inducir, entrenar y/o amplificar la respuesta inmune a los epitopes restringidos de la clase I de MHC de antigenos de carcinoma, para genera una respuesta inmune anticancerigeno efectiva.
MX2007015933A 2005-06-17 2006-06-16 Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales. MX2007015933A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69157905P 2005-06-17 2005-06-17
PCT/US2006/023498 WO2006138567A2 (en) 2005-06-17 2006-06-16 Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma

Publications (1)

Publication Number Publication Date
MX2007015933A true MX2007015933A (es) 2008-04-21

Family

ID=37325697

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007015933A MX2007015933A (es) 2005-06-17 2006-06-16 Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales.

Country Status (14)

Country Link
US (2) US7999088B2 (es)
EP (3) EP2385059A3 (es)
JP (1) JP5416968B2 (es)
KR (1) KR20080026181A (es)
CN (1) CN101198620A (es)
AU (1) AU2006259220C1 (es)
BR (1) BRPI0611794A2 (es)
CA (1) CA2612516C (es)
ES (1) ES2413079T3 (es)
IL (1) IL188113A (es)
MX (1) MX2007015933A (es)
NZ (1) NZ591908A (es)
SG (1) SG162817A1 (es)
WO (1) WO2006138567A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
EP1838338A2 (en) * 2004-12-29 2007-10-03 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
CA2592972A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
EP1833506B1 (en) * 2004-12-29 2015-08-26 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
JP5416968B2 (ja) 2005-06-17 2014-02-12 マンカインド コーポレイション 癌細胞及び腫瘍間質上に発現される優勢及び亜優勢エピトープに対する多価免疫応答を誘発するための方法及び組成物
EP1901774B1 (en) * 2005-06-17 2014-04-09 MannKind Corporation Multivalent entrain-and-amplify immunotherapeutics for carcinoma
NZ564359A (en) * 2005-06-17 2011-09-30 Mannkind Corp Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes
EP2046344A2 (en) * 2006-07-14 2009-04-15 MannKind Corporation Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
EP2125005B1 (en) 2007-03-26 2015-04-08 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Prame derived peptides and immunogenic compositions comprising these
EA201300101A1 (ru) * 2007-05-24 2014-02-28 Глаксосмитклайн Байолоджикалс С.А. Лиофилизированная антигенная композиция
AU2010310468A1 (en) * 2009-10-23 2012-05-24 Mannkind Corporation Cancer immunotherapy and method of treatment
EP2714072A1 (en) * 2011-05-26 2014-04-09 Geneius Biotechnology Investments, LLC Modulated immunodominance therapy
RU2554821C1 (ru) * 2014-02-18 2015-06-27 Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Красноярский Государственный Медицинский Университет Имени Профессора В.Ф. Войно-Ясенецкого Министерства Здравоохранения Российской Федерации" Способ оценки степени локальной холодовой травмы в раннем реактивном периоде
JP2019505512A (ja) * 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
WO2017118702A1 (en) * 2016-01-08 2017-07-13 Vaccibody As Neoepitope rna cancer vaccine
CN106367406A (zh) * 2016-08-28 2017-02-01 苏州普罗达生物科技有限公司 Udp糖基转移酶免疫原多肽及其用途
CN106581668B (zh) * 2016-12-31 2020-03-24 广州姿生生物科技有限公司 一种抗原表位肽组合物及其应用
CN115803049A (zh) * 2020-04-21 2023-03-14 磨石生物公司 抗原编码盒
CN112686128B (zh) * 2020-12-28 2022-10-14 南京览众智能科技有限公司 基于机器学习的教室课桌检测方法
MX2023012902A (es) 2021-05-05 2023-11-08 Immatics Biotechnologies Gmbh Proteinas de union a antigenos que se unen especificamente a prame.

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2606601A (en) 1948-12-14 1952-08-12 Knoll Associates Chair having a back rest in the form of a shell-like body
US6417165B1 (en) 1988-03-27 2002-07-09 Ludwig Institute For Cancer Research NY-ESO-1-peptide derivatives, and uses thereof
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1994009820A1 (en) 1992-11-05 1994-05-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5747271A (en) 1992-12-22 1998-05-05 Ludwig Institute For Cancer Research Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5620886A (en) 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5571711A (en) 1993-06-17 1996-11-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
US5858689A (en) 1993-07-22 1999-01-12 Ludwig Institute For Cancer Research Isolated peptides derived from the gage tumor rejection antigen precursor and uses thereof
US5648226A (en) 1993-07-22 1997-07-15 Ludwig Institute For Cancer Research Isolated peptides derived from tumor rejection antigens, and their use
US6013481A (en) 1993-07-22 2000-01-11 Ludwig Institute For Cancer Research Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
US5610013A (en) 1993-07-22 1997-03-11 Ludwig Institute For Cancer Research Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5935818A (en) 1995-02-24 1999-08-10 Sloan-Kettering Institute For Cancer Research Isolated nucleic acid molecule encoding alternatively spliced prostate-specific membrane antigen and uses thereof
US6660276B1 (en) 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US5512437A (en) 1994-03-01 1996-04-30 Ludwig Institute For Cancer Research Method for determining head and neck squamous cell carcinomas, prostate carcinomas, and bladder tumors by assaying for mage-3
US5512444A (en) 1994-03-01 1996-04-30 Ludwig Institute For Cancer Research Method for determining bladder tumors by assaying for MAGE-1,2,3 or 4
US5763165A (en) 1994-03-10 1998-06-09 Ludwig Institute For Cancer Research Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5837476A (en) 1995-03-03 1998-11-17 Ludwig Institute Methods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursor
US6025191A (en) 1995-06-07 2000-02-15 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US5856136A (en) 1996-07-03 1999-01-05 Incyte Pharmaceuticals, Inc. Human stem cell antigens
US5908778A (en) 1996-10-03 1999-06-01 Ludwig Institute For Cancer Research Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
US6287756B1 (en) 1997-05-05 2001-09-11 Ludwig Institute For Cancer Research Methods for determining presence of cancer in a sample by determining expression of an SSX gene
US6548064B1 (en) 1997-05-05 2003-04-15 Ludwig Institute For Cancer Research Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules
US6025470A (en) 1997-06-23 2000-02-15 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to HLA molecules, and the use thereof
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
AU739189B2 (en) 1997-07-10 2001-10-04 Mannkind Corporation A method of inducing a CTL response
US5888751A (en) 1997-07-15 1999-03-30 Ludwig Institute For Cancer Research Method for diagnosis and treating cancers, and methods for identifying pathogenic markers in a sample of normal cells
US6746839B1 (en) 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
US5985571A (en) 1998-02-04 1999-11-16 Ludwig Institute For Cancer Research Method for determining multiple myeloma by assaying for expression of mage genes
US6709844B1 (en) 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
US20030138808A1 (en) 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
US6200765B1 (en) * 1998-05-04 2001-03-13 Pacific Northwest Cancer Foundation Non-invasive methods to detect prostate cancer
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US6140050A (en) 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
ES2222728T3 (es) * 1998-10-05 2005-02-01 Pharmexa A/S Procedimiento de vacunacion terapeutica.
DK1147212T3 (da) 1999-02-05 2010-01-04 Univ Melbourne T-hjælpecelle-epitoper
HK1045700B (zh) 1999-04-28 2007-07-27 德克萨斯大学董事会 用於通过选择性抑制vegf来治疗癌症的组合物和方法
US6720146B2 (en) * 1999-09-10 2004-04-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6605711B1 (en) 1999-11-15 2003-08-12 Ludwig Institute For Cancer Research NY-ESO-1 peptide derivatives, and uses thereof
EP1118860A1 (en) 2000-01-21 2001-07-25 Rijksuniversiteit te Leiden Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
JP2003524016A (ja) * 2000-02-23 2003-08-12 エピミューン， インコーポレイテッド Ｈｌａ結合ペプチドおよびそれらの用途
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
AU5741001A (en) * 2000-04-28 2001-11-12 Ctl Immunotherapies Corp Epitope synchronization in antigen presenting cells
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
EP1372736A4 (en) * 2001-03-07 2004-11-17 Mannkind Corp PREPARATIONS AGAINST CANCER FORMATION
US20030044813A1 (en) 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
AU2002307438A1 (en) * 2001-04-20 2002-11-05 Ludwig Institute For Cancer Research Cancer-testis antigens
US6794501B2 (en) 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
ATE494387T1 (de) 2001-11-07 2011-01-15 Mannkind Corp Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
US6706405B2 (en) 2002-02-11 2004-03-16 Analytical Services & Materials, Inc. Composite coating for imparting particel erosion resistance
US6715905B2 (en) 2002-06-17 2004-04-06 Birchwood Products Limited Lighting apparatus
WO2004005891A2 (en) * 2002-07-10 2004-01-15 The Regents Of The University Of Michigan Expression profile of lung cancer
EP1545610A4 (en) * 2002-09-06 2006-11-08 Mannkind Corp EPITOPE SEQUENCES
DE602004028468D1 (de) 2003-06-17 2010-09-16 Mannkind Corp Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke
AU2004249254B2 (en) * 2003-06-17 2010-07-08 Mannkind Corporation Combinations of tumor-associated antigens for the treatment of various types of cancers
MXPA06014769A (es) 2004-06-17 2007-03-26 Mannkind Corp Eficiencia mejorada de la inmunoterapia al integrar metodos de diagnostico con terapeuticos.
WO2006009920A2 (en) 2004-06-17 2006-01-26 Mannkind Corporation Epitope analogs
US20060008468A1 (en) 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060159689A1 (en) 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
EP1838338A2 (en) 2004-12-29 2007-10-03 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
EP1833506B1 (en) 2004-12-29 2015-08-26 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
SG158154A1 (en) 2004-12-29 2010-01-29 Mannkind Corp Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
CA2592972A1 (en) * 2004-12-29 2006-07-06 Mannkind Corporation Methods to bypass cd+4 cells in the induction of an immune response
EP1901774B1 (en) 2005-06-17 2014-04-09 MannKind Corporation Multivalent entrain-and-amplify immunotherapeutics for carcinoma
JP5416968B2 (ja) 2005-06-17 2014-02-12 マンカインド コーポレイション 癌細胞及び腫瘍間質上に発現される優勢及び亜優勢エピトープに対する多価免疫応答を誘発するための方法及び組成物
NZ564359A (en) * 2005-06-17 2011-09-30 Mannkind Corp Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes
EP2046344A2 (en) * 2006-07-14 2009-04-15 MannKind Corporation Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
CA2678353A1 (en) * 2007-02-15 2008-08-21 Mannkind Corporation A method for enhancing t cell response
MX2009012635A (es) * 2007-05-23 2012-09-13 Mannkind Corp Vectores multicistronicos y metodos para su diseño.
KR101718768B1 (ko) 2009-12-21 2017-03-22 삼성전자주식회사 휴대용 단말기에서 전력 소모를 줄이기 위한 장치 및 방법
US9469902B2 (en) 2014-02-18 2016-10-18 Lam Research Corporation Electroless deposition of continuous platinum layer
US9814289B2 (en) 2015-04-08 2017-11-14 Otter Products, Llc Protective folio case for an electronic device
EP3636238B1 (en) 2018-10-12 2021-04-28 Liko Research & Development AB Gates with transition ramps for overhead lifting rails

Also Published As

Publication number Publication date
US7999088B2 (en) 2011-08-16
NZ591908A (en) 2012-09-28
WO2006138567A3 (en) 2007-02-15
EP2385059A2 (en) 2011-11-09
JP5416968B2 (ja) 2014-02-12
JP2008543315A (ja) 2008-12-04
CN101198620A (zh) 2008-06-11
US20110269949A1 (en) 2011-11-03
CA2612516A1 (en) 2006-12-28
IL188113A0 (en) 2008-03-20
WO2006138567A2 (en) 2006-12-28
AU2006259220B2 (en) 2012-10-11
KR20080026181A (ko) 2008-03-24
CA2612516C (en) 2015-03-24
US20070004662A1 (en) 2007-01-04
BRPI0611794A2 (pt) 2010-09-28
AU2006259220C1 (en) 2013-05-16
EP1896494A2 (en) 2008-03-12
ES2413079T3 (es) 2013-07-15
EP2385060A2 (en) 2011-11-09
EP2385059A3 (en) 2012-02-15
US8674081B2 (en) 2014-03-18
EP1896494B1 (en) 2013-04-03
SG162817A1 (en) 2010-07-29
EP2385060A3 (en) 2012-02-15
IL188113A (en) 2015-03-31
AU2006259220A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
MX2007015933A (es) Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales.
MX2010001054A (es) Composiciones adyuvantes antigenicas y metodos.
CY1110187T1 (el) Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ιι
MX2020004935A (es) Terapias con celulas inmunitarias multifuncionales.
TW200806316A (en) Yeast-based vaccine for inducing an immune response
ATE421533T1 (de) Immunogene t-helfer epitope von menschlichen tumorantigenen und deren verwendung in immunotherapeutischen methoden
WO2008039874A3 (en) Cancer stem cell antigen vaccines and methods
MX363307B (es) Plataformas para suministro de antigenos.
DE602006019446D1 (de) An humane leukozytenantigen-(hla-)klasse-i- oder ii-moleküle bindende tumorassoziierte peptide und damit im zusammenhang stehender impfstoff gegen krebs
NO20070699L (no) Spesielle aminoalkylglukosaminidfosfatforbindelser og deres anvendelse
MX375202B (es) Composiciones adyuvantes novedosas.
BRPI0915076A2 (pt) composições de vacina, composição imunogênica, método para expressão dos antígenos quiméricos de hpv-hbsag supramencionados, composição farmacêutica, método para ocasionar resposta de anticorpo protetor para composição antigênica e/ou resposta de célula t citotóxica, uso das formulações antigênicas supramencionadas.
GB2434367A (en) Improved vaccines
MX2016001695A (es) Composiciones inmunogenas de combinacion.
CL2019000019A1 (es) Anticuerpos con baja inmunogenicidad y uso de los mismos
EA200900738A1 (ru) Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1
SG162818A1 (en) Multivalent entrain-and-amplify immunotherapeutics for carcinoma
WO2008008541A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
CO6341568A2 (es) Composicion inmunologica
AR117191A1 (es) Composiciones inmunogénicas

Legal Events

Date Code Title Description
FG Grant or registration